Merck: agreement with China's Hansoh Pharma on GLP-1

(CercleFinance.com) - Merck announced on Wednesday the signature of a worldwide licensing agreement with Hansoh Pharma, with the aim of developing the experimental GLP-1 tablet developed by the Chinese pharmaceutical company.


With the signature of this agreement, the American group says it wants to strengthen its expertise in the field of incretin treatments, but also to study the potential of HS-10535, a small molecule designed for weight loss by Hansoh, on cardiometabolism.

In detail, Hansoh Pharma has granted Merck exclusive rights to develop, manufacture and market HS-10535 in return for an upfront payment of $112 million.

Hansoh, which has reserved the rights for China, could receive a total of $1.9 billion from Merck depending on the progress of the project, not including possible royalties on future sales of the product.

Copyright (c) 2024 CercleFinance.com. All rights reserved.